Biotest AG Prepares Yimmugo Launch in the USA, Secures Strategic Deal with Kedrion

Biotest AG announces the upcoming launch of its immunoglobulin product, Yimmugo®, in the U.S. The framework for a billion-dollar distribution agreement with Kedrion has been established following FDA approval on June 13, 2024. The production of launch quantities has begun, and shipments to the U.S. are expected in Q4 2024, with market entry planned for Q1 2025.

The agreement is anticipated to generate over $1 billion in revenue for Biotest during its seven-year term. Yimmugo® is the first of several new proteins from Biotest, with others like fibrinogen and trimodulin also in late-stage development. CEO Peter Janssen expressed confidence in the commercial success of Yimmugo® in the U.S. market.

Yimmugo® will be the first drug manufactured using Biotest's innovative "Next Level" facility process. This collaboration spotlights Kedrion’s experience and Biotest's commitment to expanding patient access to immunoglobulin therapies in the U.S.